In parallel with our meta-analysis, Mukherjee et al. reported that no statistically significant difference was noted in MACE, stroke, MI, or death at 6 months between those receiving a CYP3A4 metabolized or non-CYP3A4 metabolized statin with clopidogrel therapy [26]. The gene discussed is CYP3A4; the disease is Stroke.